{"type":"trials","record":{"id":43213,"source_id":"clinicaltrials-gov","external_id":"NCT03219593","title":"Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer","brief_summary":"The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to chemotherapy, through progression-free survival (PFS). Apatinib will be given to patients with an efficacy assessment of stable disease (SD), partial response (PR), or complete response (CR) every 2 cycles. Patients were assigned to 500 mg/d apatinib continually until disease progression or intolerable toxicity or patients withdrawal of consent. The dose of apatinib may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg, and the sample size is about 30 individuals. Tumor tissue samples will be collected from each enrolled subjects before the start of treatment, and detected using next generation sequencing (NGS)-based comprehensive genomic profiling. The potential biomarkers in predicting apatinib efficacy or safety will be explored.","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"The First Affiliated Hospital of Bengbu Medical University","enrollment":30,"countries":["China"],"start_date":"2017-09-07","completion_date":"2027-09-01","last_update_date":"2026-09-08","source_url":"https://clinicaltrials.gov/study/NCT03219593","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:40.376869+00:00","last_seen_at":"2026-09-25T03:15:05.717+00:00","metadata":{"acronym":null,"organization":"The First Affiliated Hospital of Bengbu Medical University","source_has_results":false},"controlled_terms":["Gastric Cancer","Apatinib","Biomarker","Apatinib mesylate tablets"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: cancer.","quality_checked_at":"2026-09-25T03:15:14.669058+00:00","duplicate_cluster_key":"id:nct03219593","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2017-09-07 to 2027-09-01","comparator":null,"confidence":"structured-source","population":null,"provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:39:00.171371+00:00","intervention":[],"participants":30,"study_design":"INTERVENTIONAL","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":[],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"cancer-and-aging","is_published":true,"match_reasons":["Title contains controlled term: cancer.","Abstract contains controlled term: tumor.","Source terminology contains: cancer.","Title supplies longevity context: elderly.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Cancer and ageing","slug":"cancer-and-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/43213","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}